Rocbrutinib
Phase 3Small molecule
Rocbrutinib is one of 159 small molecule programs targeting Tics. It is currently in Phase 3.
5
Indications
8
Total Trials
8
Active Trials
158
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
108 competitors in Tics
#DrugCompanyPhaseTrials
1Sodium Valproate
AstraZenecaPhase 3
Rifadin
SanofiPhase 1
Priftin
SanofiPhase 2
Rocbrutinib
GGuangzhou Lupeng Pharmaceutical Company LTD.
Phase 3
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Duvyzat
ItalfarmacoPhase 2
Dilaudid
RRhodes Pharmaceuticals, L.P.
Phase 2
DTIC-Dome
BayerPhase 1
Taltz
Eli LillyPhase 1
Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Mantle Cell Lymphoma2 trials
A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma
Active, not recruiting·GGuangzhou Lupeng Pharmaceutical Company LTD.·Phase 2·NCT05716087·62 enrolled
Diffuse Large B-Cell Lymphoma1 trial
Tics1 trial
B-cell Non Hodgkin Lymphoma1 trial
A Phase Ib Study to Assess Safety and Preliminary Efficacy of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-NHL
Active, not recruiting·GGuangzhou Lupeng Pharmaceutical Company LTD.·Phase 1·NCT06251180·112 enrolled
DLBCL1 trial
2 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rocbrutinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details